NCT01161745

Brief Summary

The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2008

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2008

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2010

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2010

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

July 13, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 14, 2010

Completed
Last Updated

July 14, 2010

Status Verified

June 1, 2010

Enrollment Period

1.2 years

First QC Date

July 13, 2010

Last Update Submit

July 13, 2010

Conditions

Sepsis

Keywords

sepsis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients who develop sepsis

You may qualify if:

  • patients who develop sepsis

You may not qualify if:

  • patients with cirrhosis or renal dysfunction
  • patients with dyscrasia
  • patients with autoimmunity diseases
  • patients with severe cardiac and pulmonary diseases
  • patients with hematological diseases
  • patients with diabetes mellitus
  • patients with malignant tumors

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

peripheral venous blood from septic patients and healthy controls, anticoagulate with EDTA-K2

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Xiao-ming Deng, doctor

    Changhai Hospital, the Second Military Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 13, 2010

First Posted

July 14, 2010

Study Start

December 1, 2008

Primary Completion

February 1, 2010

Study Completion

April 1, 2010

Last Updated

July 14, 2010

Record last verified: 2010-06